Deferasirox

Bezeichnung:Deferasirox

CAS-Nr201530-41-8

Englisch Name:Deferasirox

CBNumberCB7855359

SummenformelC21H15N3O4

Molgewicht373.36

MOL-Datei201530-41-8.mol

Deferasirox physikalisch-chemischer Eigenschaften

Schmelzpunkt	260-2620C
Siedepunkt	672.1±65.0 °C(Predicted)
Dichte	1.40±0.1 g/cm3(Predicted)
storage temp.	Keep in dark place,Inert atmosphere,2-8°C
Löslichkeit	Soluble in DMSO (10 mg/ml)
Aggregatzustand	solid
pka	pKa1 4.57, pKa2 8.71, pKa3 10.56 (Nick); Also reported in H2O/DMSO (CDMSO = 0.20) as pKa1 4.61, pKa2 10.12, pKa3 12.08 (Steinhauser)
Farbe	Off-white to white
Stabilität	Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.

Sicherheit

HS Code	2933997500
Giftige Stoffe Daten	201530-41-8(Hazardous Substances Data)

Gefahreninformationscode (GHS)

Deferasirox Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Linagliptin was originally discovered at Boehringer Ingelheim as an orally active dipeptidyl peptidase-IV (DPP-4) inhibitor. Eli Lilly and Boehringer Ingelheim co-developed and launched linagliptin for type II diabetes as an adjunct to diet and exercise for the improvement of adult glycemic control. Linagliptin has a superior DPP-4 IC50 value of 1 nM, compared with 19 nM for sitagliptin, 24 nM for alogliptin, 50 nM for saxagliptin and 62 nM for vildagliptin. In addition, linagliptin exhibited prolonged pharmacodynamic activity with long-lasting DPP-4 inhibition in several preclinical species. Linagliptin showed good efficacy in phase II clinical trials with doses as low as 5 mg and no signs of hypoglycemia with doses as high as 600 mg. The prolonged pharmacological effect of DPP-4 activity and the good safety/tolerability profile provided the basis for linagliptin’s approval.
Chemische Eigenschaften
White to Off-White Solid
Originator
Novartis (Switzerland)
Verwenden
A tridentate chelator that binds iron with high affinity
Verwenden
Orally active tridentate iron chelator
Verwenden
Labeled Deferasirox, intended for use as an internal standard for the quantification of Deferasirox by GC- or LC-mass spectrometry.
Verwenden
Biological Activity Chemical Information Tech Support & FAQs Biological Activity Deferasirox(Exjade) is a rationally-designed oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions
Definition
ChEBI: A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patient receiving long-term blood transfusions.
Trademarks
Exjade (Novartis).
Clinical Use
Treatment of iron overload
Synthese
Synthesis of deferasirox started with cyclization of salicylamide (26) with salicyloyl chloride (27) by heating at 170 C without any solvents to give 2-(2-hydroxyphenyl)-benz[e]oxazin-4-one (28) in 55% yield. Compound 28 was reacted with 4-hydrazinobenzoic acid (29) in refluxing ethanol for 2 hours to give deferasirox V as colorless crystals.
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Aluminium-containing antacids: avoid concomitant use.
Aminophylline and theophylline: concentration of aminophylline and theophylline increased, consider reducing aminophylline and theophylline dose.
Other nephrotoxic agents: avoid concomitant therapy
Stoffwechsel
Metabolism of deferasirox is mainly glucuronidation by uridine diphosphate glucuronosyltransferase (UGT) enzymes. Cytochrome P450 isoenzyme-mediated metabolism appears to be minor. Deconjugation of the glucuronidates in the intestine and subsequent enterohepatic recycling are likely to occur. It is excreted mainly in the faeces via bile, as metabolites and as unchanged drug. About 8% of a dose is excreted in the urine.
Einzelnachweise
Heinz et al. (1999), 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid: A Novel Efficient and Selective Iron(III) Complexing Agent; Ang. Chem. Int. Ed., 38 2568 Palumbo et al. (2021), From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox; Front. Oncol., 11 752192 Roatsch et al. (2019), The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases; ACS Chem. Biol., 14 1737 Lui et al. (2015), Targeting cancer by binding iron: Dissecting cellular signaling pathways; Oncotarget, 6 18748 Ibrahim and O’Sullivan (2020), Iron chelators in cancer therapy; Biometals, 33 201 Szymonik et al. (2021), The Impact of Iron Chelators on the Biology of Cancer Stem Cells; Int. J. Mol. Sci., 23 89

Deferasirox Upstream-Materialien And Downstream Produkte

Deferasirox Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

201530-41-8, Deferasirox Verwandte Suche:

Send Inquriy